Aflibercept

Generic Name
Aflibercept
Brand Names
Eylea, Zaltrap, Yesafili
Drug Type
Biotech
Chemical Formula
-
CAS Number
862111-32-8
Unique Ingredient Identifier
15C2VL427D
Background

Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors, VEGFR1 and VEGFR2, fused with the Fc region of human immunoglobulin gamma 1 (IgG1). Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Daltons (kDa). It contains approximately 15% glycosylation to give a total molecular weight of 115 kDa. All five putative N-glycosylation sites on each polypeptide chain predicted by the primary sequence can be occupied with carbohydrates and exhibit some degree of chain heterogeneity, including heterogeneity in terminal sialic acid residues, except at the single unsialylated site associated with the Fc domain. Due to the 2 fused VEGFR, aflibercept has a higher affinity to the cognate ligands than the endogenous individual receptor. However, it lacks the intracellular structure to propagate subsequent signal transduction, thus essentially sequestering the ligands to prevent activation of VEGFR.

Ziv-aflibercept, under the brand name Zaltrap, was developed as an intravenous injection for the treatment of metastatic colorectal cancer, and it was approved by the FDA and EMA in August 2012 and February 2013, respectively. The intravitreal formulation, under the brand name EYELEA, was approved by the FDA for the treatment of retinopathy of prematurity in preterm infants in February 2023 and for the treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy in August 2023.

Indication

The opthalmic agent is used for the treatment of neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR), and retinopathy of prematurity (ROP).

The systemic injection, known as ziv-aflibercept, in combination with 5-fluorouracil, leucovorin, irinotecan-(FOLFIRI), is for the treatment of metastatic colorectal cancer that is resistant to or progressed following treatment with oxaliplatin.

Associated Conditions
Branch Retinal Vein Occlusion With Macular Edema, Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), Macular Edema, Macular Edema With Central Retinal Vein Occlusions, Metastatic Colorectal Cancer (CRC), Myopic Choroidal Neovascularization, Neovascular Age-Related Macular Degeneration (nAMD), Retinopathy of Prematurity (ROP)
Associated Therapies
-

Role of Intravitreal Aflibercept Injection for the Treatment of Radiation Maculopathy

Phase 2
Completed
Conditions
Interventions
First Posted Date
2015-10-26
Last Posted Date
2023-10-19
Lead Sponsor
Larkin Community Hospital
Target Recruit Count
40
Registration Number
NCT02586727

Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab

Phase 4
Completed
Conditions
Interventions
First Posted Date
2015-09-24
Last Posted Date
2023-03-30
Lead Sponsor
Rishi Singh
Target Recruit Count
20
Registration Number
NCT02559180
Locations
🇺🇸

Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, United States

Study Evaluating the Efficacy of Aflibercept for the Treatment of Inflammatory CNV in Young Patients (ALINEA).

Phase 2
Completed
Conditions
Interventions
First Posted Date
2015-09-22
Last Posted Date
2019-11-07
Lead Sponsor
Hospices Civils de Lyon
Target Recruit Count
20
Registration Number
NCT02556229
Locations
🇫🇷

Hospices Civils de Lyon / Hopital de la Croix Rousse, Lyon, France

Comparison of Treatment rOutine Using afLibERcept: Strict vs relAxed retreatmeNT Regimen

First Posted Date
2015-09-15
Last Posted Date
2022-12-01
Lead Sponsor
Insel Gruppe AG, University Hospital Bern
Target Recruit Count
150
Registration Number
NCT02550002
Locations
🇨🇭

Department of Ophthalmology, University Hospital Bern, Bern, Switzerland

🇨🇭

Inselspital Bern, Department of Ophthalmology, Bern, Switzerland

Intravitreal Aflibercept for Therapy of Patients With Pseudoxanthoma Elasticum (PXE)

Phase 2
Completed
Conditions
Interventions
First Posted Date
2015-09-01
Last Posted Date
2019-05-07
Lead Sponsor
University Hospital, Bonn
Target Recruit Count
15
Registration Number
NCT02537054
Locations
🇩🇪

Department of Ophthalmology, Universtiy of Bonn, Bonn, Germany

Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO

First Posted Date
2015-07-21
Last Posted Date
2021-05-12
Lead Sponsor
Justis Ehlers
Target Recruit Count
31
Registration Number
NCT02503540
Locations
🇺🇸

Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, United States

Ziv-aflibercept in Ocular Disease Requiring Anti-VEGF Injection

First Posted Date
2015-07-01
Last Posted Date
2018-08-29
Lead Sponsor
Rafic Hariri University Hospital
Target Recruit Count
100
Registration Number
NCT02486484
Locations
🇱🇧

Rafic Hariri University Hospital, Beirut, Lebanon

Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMD

First Posted Date
2015-05-29
Last Posted Date
2017-07-26
Lead Sponsor
Duke University
Registration Number
NCT02457026
Locations
🇺🇸

Duke Eye Center, Durham, North Carolina, United States

Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Diabetic Macular Edema

Phase 4
Completed
Conditions
Interventions
First Posted Date
2015-05-12
Last Posted Date
2019-09-19
Lead Sponsor
Unity Health Toronto
Target Recruit Count
16
Registration Number
NCT02441907
Locations
🇨🇦

St. Michael's Hospital Eye Clinic, Toronto, Ontario, Canada

© Copyright 2024. All Rights Reserved by MedPath